Duavive Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

duavive

pfizer europe ma eeig - oestrogens konjugiran, bazedoxifene - postmenopavza - konjugiran estrogenov in bazedoxifene - duavive je indicirano za:zdravljenje oestrogen pomanjkljivost simptomi pri ženskah po menopavzi z maternico (z najmanj 12 mesecev od zadnjega menses), za katere zdravljenje z progestin, ki vsebujejo terapija ni primerna,. izkušnje zdravljenju žensk, starejših od 65 let, je omejeno.

Incurin Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

incurin

intervet international bv - estriol - spolni hormoni in modulatorji genitalnega sistema - psi - zdravljenje hormonsko odvisne urinske inkontinence zaradi nesposobnosti mehanizma sfinktra pri ovariohisterektomiranih psicah.

Senshio Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

senshio

shionogi b.v. - ospemifen - postmenopavza - spolni hormoni in zdravila genitalni sistem, - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.

Intrarosa Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

intrarosa

endoceutics s.a. - prasterone - postmenopavza - drugi spolni hormoni in zdravila genitalni sistem - intrarosa je indicirano za zdravljenje vulve in vaginalne atrofije v menopavzi, ki imajo zmerno do hudo simptomi.

Ryeqo Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

ryeqo

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyoma - hipofize in hipotalamični hormoni in analogi - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Yselty Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

yselty

theramex ireland limited - linzagolix choline - leiomyoma - hipofize in hipotalamični hormoni in analogi - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Faslodex Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

faslodex

astrazeneca ab - fulvestrant - neoplazme dojke - endokrini terapije, anti-estrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - ali perimenopausal ženske, kombinacija zdravljenja z palbociclib je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.